Impact of skeletal complications on patients' quality of life, mobility, and functional independence.
Affiliation
Instituto de Medicina Molecular-Lisboa, Servico de Oncologia, Hospital de Santa Maria, Av Professor Egaz Moniz, Lisbon, 1649-039, Portugal. luiscosta.p@netcabo.ptIssue Date
2008-08
Metadata
Show full item recordAbstract
INTRODUCTION: Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life. DISCUSSION: Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.Citation
Impact of skeletal complications on patients' quality of life, mobility, and functional independence. 2008, 16 (8):879-89 Support Care CancerJournal
Supportive Care in CancerDOI
10.1007/s00520-008-0418-0PubMed ID
18392862Type
ArticleLanguage
enISSN
0941-4355ae974a485f413a2113503eed53cd6c53
10.1007/s00520-008-0418-0
Scopus Count
Related articles
- Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.
- Authors: Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE
- Issue date: 2010 Oct
- Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
- Authors: Costa L
- Issue date: 2007 Dec
- Predicting skeletal complications in metastatic breast cancer raises challenges.
- Authors: Van Poznak C
- Issue date: 2010 Oct
- Optimal management of metastatic bone disease.
- Authors: Major P
- Issue date: 2007
- Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.
- Authors: Saad F
- Issue date: 2005 Jun